Welcome to our dedicated page for Nurix Therapeutics news (Ticker: NRIX), a resource for investors and traders seeking the latest updates and insights on Nurix Therapeutics stock.
Nurix Therapeutics, Inc. reports developments as a clinical-stage biopharmaceutical company developing targeted protein degradation medicines for oncology and autoimmune and inflammatory diseases. News commonly centers on bexobrutideg (NX-5948), a Bruton’s tyrosine kinase degrader, including clinical data in chronic lymphocytic leukemia, small lymphocytic lymphoma and Waldenström macroglobulinemia, as well as updates tied to the DAYBreak development program.
Company updates also cover Nurix’s DEL-AI discovery platform, preclinical degrader programs against targets such as pan-mutant BRAF, CBL-B and Aurora kinase A, and partnered inflammation and immunology programs involving IRAK4 and STAT6 degraders. Recurring announcements include financial results, corporate presentations, scientific meeting data, pipeline progress, capital actions and board or governance changes.
Nurix Therapeutics announced the pricing of its initial public offering of 11,000,000 shares at $19.00 per share, aiming for gross proceeds of approximately $209 million.
The shares are set to trade on The Nasdaq Global Market under the symbol NRIX starting July 24, 2020. Additionally, underwriters have a 30-day option to buy up to 1,650,000 more shares at the IPO price. The offering is expected to close by July 28, 2020, pending customary closing conditions.